Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J6AB
|
||||
| Former ID |
DCL000572
|
||||
| Drug Name |
MK-5108
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H21ClFN3O3S
|
||||
| InChI |
InChI=1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)
|
||||
| InChIKey |
LCVIRAZGMYMNNT-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
49650216, 50082338, 136345851, 136367506, 136946400, 140461525, 141492910, 144116230, 152159565, 152258490, 160647325, 162011959, 164193996, 172650685, 174006374, 177749657, 186014854, 186526079, 189561491, 198943204, 223389038, 223705109, 227705685, 227705688, 242060386, 242585457, 246152918, 246268388, 249565741, 251963164, 252160606, 252215822, 252451773, 252552935
|
||||
| Target and Pathway | |||||
| Target(s) | Aurora kinase B | Target Info | Inhibitor | [549718], [550064] | |
| Aurora kinase A | Target Info | Inhibitor | [549718], [550064] | ||
| KEGG Pathway | Oocyte meiosis | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | ||||
| Separation of Sister Chromatids | |||||
| Resolution of Sister Chromatid Cohesion | |||||
| RHO GTPases Activate Formins | |||||
| Mitotic PrometaphaseR-HSA-174178:APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| WikiPathways | Mitotic Metaphase and Anaphase | ||||
| Mitotic Prometaphase | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| miR-targeted genes in lymphocytes - TarBase | |||||
| miR-targeted genes in epithelium - TarBase | |||||
| APC/C-mediated degradation of cell cycle proteinsWP437:EGF/EGFR Signaling Pathway | |||||
| JAK/STAT | |||||
| Gastric Cancer Network 1 | |||||
| Integrated Breast Cancer Pathway | |||||
| APC/C-mediated degradation of cell cycle proteins | |||||
| References | |||||
| Ref 542949 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8061). | ||||
| Ref 548558 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026594) | ||||
| Ref 549718 | A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. | ||||
| Ref 550064 | Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014 Jul;140(7):1137-49. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.